Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention (FACTPCI)
Primary Purpose
Percutaneous Coronary Intervention
Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Fentanyl
Ticagrelor 90Mg Tablet
Sponsored by

About this trial
This is an interventional treatment trial for Percutaneous Coronary Intervention
Eligibility Criteria
Inclusion Criteria:
- Undergoing clinically indicated elective or non-elective PCI
- Able to swallow oral medications
Exclusion Criteria:
- Contraindications to ticagrelor or fentanyl (or other opiates)
- Pregnancy
- Any use of P2Y12 inhibitors within 14 days
- Known coagulation disorders
- Pre-procedural treatment with an anticoagulant (oral anticoagulant or low molecular weight heparin)
- Platelet count < 100,000/mm3
- Impaired renal function (Estimated glomerular filtration < 45 ml/min/1.73 m2)
- Impaired hepatic function (Based on medical history)
- Prior or planned transcatheter aortic valve replacement
Sites / Locations
- The Guthrie ClinicRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Fentanyl and Crushed Ticagrelor
Fentanyl and Non-crushed Ticagrelor
Arm Description
Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
Outcomes
Primary Outcome Measures
Platelet Function Testing
Platelet vasodilator-stimulated phosphoprotein assay
Secondary Outcome Measures
Stent thrombosis
Recurrent myocardial infarction
All-cause mortality
Stroke
TIMI minor and major
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03476369
Brief Title
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
Acronym
FACTPCI
Official Title
A Randomized Controlled Trial of Patients Undergoing Percutaneous Coronary Intervention Who Receive Ticagrelor and Fentanyl
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 18, 2018 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Guthrie Clinic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Percutaneous Coronary Intervention
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fentanyl and Crushed Ticagrelor
Arm Type
Experimental
Arm Description
Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
Arm Title
Fentanyl and Non-crushed Ticagrelor
Arm Type
Active Comparator
Arm Description
Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
Intervention Type
Drug
Intervention Name(s)
Fentanyl
Intervention Description
Premedicated with Fentanyl (at least 25mcg by IV)
Intervention Type
Drug
Intervention Name(s)
Ticagrelor 90Mg Tablet
Intervention Description
Ticagrelor administered crushed vs non-crushed
Primary Outcome Measure Information:
Title
Platelet Function Testing
Description
Platelet vasodilator-stimulated phosphoprotein assay
Time Frame
6 hours
Secondary Outcome Measure Information:
Title
Stent thrombosis
Time Frame
30 days
Title
Recurrent myocardial infarction
Time Frame
30 days
Title
All-cause mortality
Time Frame
30 days
Title
Stroke
Time Frame
30 days
Title
TIMI minor and major
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Undergoing clinically indicated elective or non-elective PCI
Able to swallow oral medications
Exclusion Criteria:
Contraindications to ticagrelor or fentanyl (or other opiates)
Pregnancy
Any use of P2Y12 inhibitors within 14 days
Known coagulation disorders
Pre-procedural treatment with an anticoagulant (oral anticoagulant or low molecular weight heparin)
Platelet count < 100,000/mm3
Impaired renal function (Estimated glomerular filtration < 45 ml/min/1.73 m2)
Impaired hepatic function (Based on medical history)
Prior or planned transcatheter aortic valve replacement
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sudhakar Sattur, MD
Phone
570-887-6072
Email
Sudhakar.Sattur@guthrie.org
Facility Information:
Facility Name
The Guthrie Clinic
City
Sayre
State/Province
Pennsylvania
ZIP/Postal Code
18840
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vicky Hickey
Phone
570-887-4882
Email
Vicky.Hickey@guthrie.org
First Name & Middle Initial & Last Name & Degree
Sudhakar Sattur, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
We'll reach out to this number within 24 hrs